BC Week In Review | Apr 15, 2013
Company News

Microcide, Pfizer deal

MCDE will receive a $1 million payment in March for achieving its first research milestone under a March 1996 agreement with Pfizer. MCDE identified, validated and sequenced an agreed upon number of bacterial genes essential...
BioCentury | Oct 31, 2005
Finance

Ebb & Flow

Cerimon's $70 million series A round probably turned some heads last week, as the company's lone products are topical formulations of diclofenac, an NSAID that's rather long of tooth. However, the company's directors and investors...
BioCentury | Dec 24, 2001
Product Development

Infectious metrics

There was a period during the mid-1990s when biotech companies focused on infectious diseases were hot. According to the mantra, it was going to be a slam dunk to develop new antibiotics because preclinical work...
BC Week In Review | Dec 3, 2001
Company News

Genteric management update

Genteric Inc., Alameda, Calif.   Business: Gene/Cell therapy   Hired: Donald Huffman as CFO and VP of finance and administration, formerly CFO and VP of finance and corporate development at Microcide Pharmaceuticals Inc.  ...
BioCentury | Nov 12, 2001
Finance

Sleep and dreams

News that Cephalon (CEPH) beat the third quarter consensus estimates by a more than robust $0.34 might have given the impression that analysts were asleep at the wheel. It's not every day that a company...
BC Week In Review | Oct 29, 2001
Company News

Althexis Co. Inc., Microcide deal

MCDE shareholders approved the previously announced merger with Althexis and a $60 million private funding round (see BioCentury, Aug. 6). The new company will be called Essential Therapeutics Inc. and will trade on NASDAQ under...
BC Extra | Oct 25, 2001
Financial News

MCDE, Althexis complete merger, raise money

Microcide (MCDE) and Althexis completed their previously announced merger, and raised $57 million from Prospect Venture Partners; New Enterprise Associates; and Schroder Ventures. The combined company was renamed Essential Therapeutics, and is expected to begin...
BC Week In Review | Oct 8, 2001
Company News

Microcide, J&J deal

Under a January agreement, MCDE received a milestone from JNJ subsidiaries Otho-McNeil Pharmaceutical Inc. and the R.W. Johnson Pharmaceutical Research Institute, triggered by preclinical development of orally-active cephalosporin to treat resistant bacterial strains common to...
BioCentury | Sep 24, 2001
Tools & Techniques

Virtual ICAAC

The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which had been scheduled for this week, was postponed until Dec. 16-19 in the aftermath of the World Trade Center attack. However, a look through the...
BioCentury | Sep 4, 2001
Strategy

Back to School: Integration

Every year, at the end of Summer, BioCentury publishes its "Back-to-School" Commentary, which focuses on themes that we think have major strategic importance to the biotech industry. This year's 9th annual report focuses on value...
Items per page:
1 - 10 of 69
BC Week In Review | Apr 15, 2013
Company News

Microcide, Pfizer deal

MCDE will receive a $1 million payment in March for achieving its first research milestone under a March 1996 agreement with Pfizer. MCDE identified, validated and sequenced an agreed upon number of bacterial genes essential...
BioCentury | Oct 31, 2005
Finance

Ebb & Flow

Cerimon's $70 million series A round probably turned some heads last week, as the company's lone products are topical formulations of diclofenac, an NSAID that's rather long of tooth. However, the company's directors and investors...
BioCentury | Dec 24, 2001
Product Development

Infectious metrics

There was a period during the mid-1990s when biotech companies focused on infectious diseases were hot. According to the mantra, it was going to be a slam dunk to develop new antibiotics because preclinical work...
BC Week In Review | Dec 3, 2001
Company News

Genteric management update

Genteric Inc., Alameda, Calif.   Business: Gene/Cell therapy   Hired: Donald Huffman as CFO and VP of finance and administration, formerly CFO and VP of finance and corporate development at Microcide Pharmaceuticals Inc.  ...
BioCentury | Nov 12, 2001
Finance

Sleep and dreams

News that Cephalon (CEPH) beat the third quarter consensus estimates by a more than robust $0.34 might have given the impression that analysts were asleep at the wheel. It's not every day that a company...
BC Week In Review | Oct 29, 2001
Company News

Althexis Co. Inc., Microcide deal

MCDE shareholders approved the previously announced merger with Althexis and a $60 million private funding round (see BioCentury, Aug. 6). The new company will be called Essential Therapeutics Inc. and will trade on NASDAQ under...
BC Extra | Oct 25, 2001
Financial News

MCDE, Althexis complete merger, raise money

Microcide (MCDE) and Althexis completed their previously announced merger, and raised $57 million from Prospect Venture Partners; New Enterprise Associates; and Schroder Ventures. The combined company was renamed Essential Therapeutics, and is expected to begin...
BC Week In Review | Oct 8, 2001
Company News

Microcide, J&J deal

Under a January agreement, MCDE received a milestone from JNJ subsidiaries Otho-McNeil Pharmaceutical Inc. and the R.W. Johnson Pharmaceutical Research Institute, triggered by preclinical development of orally-active cephalosporin to treat resistant bacterial strains common to...
BioCentury | Sep 24, 2001
Tools & Techniques

Virtual ICAAC

The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which had been scheduled for this week, was postponed until Dec. 16-19 in the aftermath of the World Trade Center attack. However, a look through the...
BioCentury | Sep 4, 2001
Strategy

Back to School: Integration

Every year, at the end of Summer, BioCentury publishes its "Back-to-School" Commentary, which focuses on themes that we think have major strategic importance to the biotech industry. This year's 9th annual report focuses on value...
Items per page:
1 - 10 of 69